We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aura Biosciences Inc | NASDAQ:AURA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.15 | -2.11% | 6.95 | 6.67 | 7.98 | 7.09 | 6.64 | 7.07 | 180,408 | 21:00:10 |
By Stephen Nakrosis
Aura Biosciences on Monday said it received agreement from the U.S. Food and Drug Administration for the design and plan of a Phase 3 trial of belzupacap sarotalocan as a treatment for patients with early-stage choroidal melanoma.
The company said it received the agreement from the FDA for the CoMpass phase 3 clinical trial of belzupacap sarotalocan, or Bel-sar, under a special protocol assessment.
If successful, Aura said, the trial could address the objectives necessary to support the company's planned biologics license application submission for Bel-sar as a treatment for choroidal melanoma, which is a form of eye cancer.
Aura said it presented "positive Phase 2 safety and efficacy data of Bel-sar" at the American Academy of Ophthalmology meeting in San Francisco.
Also on Monday, Aura said preliminary data from a phase 1 trial in bladder cancer showed the first patient using a single dose of Bel-sar with light activation demonstrated a clinical complete response "demonstrated by absence of cancer cells on histopathology with evidence of extensive necrosis and immune activation."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 06, 2023 15:35 ET (20:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Aura Biosciences Chart |
1 Month Aura Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions